替尔泊肽降糖这么猛，正常人使用为何不会低血糖？

Core Viewpoint - The article discusses the dual agonist therapy of Tirzepatide, which targets both GIP and GLP-1 receptors, highlighting its effectiveness in managing blood sugar levels and aiding weight loss in patients with type 2 diabetes [5][12]. Mechanism of Action - Tirzepatide mimics the actions of GLP-1 and GIP, promoting insulin secretion when blood sugar levels are elevated and suppressing glucagon secretion when blood sugar is normal, thus maintaining glucose balance [5][7]. - The glucose-dependent mechanism of Tirzepatide ensures that it does not induce hypoglycemia in individuals with normal blood sugar levels, making it a safer option for treating type 2 diabetes and obesity [7]. Clinical Efficacy - Clinical studies indicate that Tirzepatide significantly improves insulin sensitivity and beta-cell function in type 2 diabetes patients, with a reduction in HbA1c levels by an average of 2.0%-2.5% [10]. - In head-to-head studies, Tirzepatide demonstrated superior efficacy in lowering HbA1c compared to Semaglutide, with a reduction of 2.46% in the 15mg group versus 1.86% in the 1mg Semaglutide group [11]. Benefits of Dual Targeting - The dual action of Tirzepatide on both GIP and GLP-1 receptors enhances its effectiveness in weight loss and blood sugar control, as GIP plays a crucial role in insulin secretion [12][14]. - Research shows that GIP contributes to approximately 44% of insulin secretion post-glucose intake, while GLP-1 accounts for only 22%, emphasizing the importance of GIP in diabetes treatment [12]. Administration and Safety - Tirzepatide has a half-life of 5 days, allowing for once-weekly administration, which improves patient adherence to treatment [14][15]. - The safety profile of Tirzepatide is comparable to other GLP-1 receptor agonists, with common gastrointestinal side effects such as nausea and diarrhea [15].